Passionate about
quality, research, and
innovation

Our expertise,
your quality
of life

Remarkable
and
unceasing
expansion

Elevating healthcare
through
international
partnerships

Through our relentless dedication, we have emerged as frontrunners in the fields of oncology, hematology, transplant cases, and rare diseases. Since 2004, we have proudly partnered with over 15 international companies and extended our reach to several other Latin American nations.

Our Commitment to
Excellence

Our primary focus is on developing and manufacturing high-quality pharmaceuticals, driven by an unwavering commitment to optimizing patient care. Our distinguished reputation stems from long-standing collaborations with the medical and scientific communities, where we prioritize innovation and continuous improvement in line with rigorous international quality standards.

Global and Latin American Products

+

360

registered
products worldwide

+

330

products in
Latin America

1

News

UY CL EC PE ARG
06.2024

Another year participating in the American Society of Clinical Oncology (ASCO) annual meeting!

In Varifarma we continue to take part in scientific events to stay at the forefront of new healthcare innovations.

UY ARG PE
06.2024

Introducing Endopredict, the prognostic test for Breast Cancer!

Find the latest news of this innovative test as a genomic tool to evaluate tumour behavior over the years for an accurate choice of treatment.

UY
05.2024

Varifarma at the Second Integrated Conference of the Academic Hematology Unit

Present at the “Daily Hematology” Conference in Montevideo from April 24 to 26.

UY PER
04.2024

myChoice CDx Plus, recognized with Level of Evidence 1A

Our genomic test myChoice CDx Plus has been recognized by the ESGO-ESMO-ESP 2024 consensus with a Level of Evidence 1A.

ARG
04.2024

Launch of GORAX® at the International Symposium of the SAU

Varifarma launched GORAX® (Relugolix) at the International Symposium “Advances in Urology 2024” organized by the Argentine Society of Urology.

ARG
03.2024

Innovation Arriving to Advanced Prostate Cancer Treatment

We Launched Gorax (Relugolix) 120mg, the first LHRH antagonist with oral intake in Argentina.
Developed by Varifarma, Gorax is a revolutionary breakthrough in advanced prostate cancer treatment.

ARG
02.2024

News in Haematology! We’re Launching Phelinum (Melphalan)

A new therapeutic alternative with multiple indications arrives to Varifarma!

ARG
02.2024

Our new presentation of Tepadina in Argentina!

We continue to increase our treatment options for our patients! We’re launching Tepadina 400mg.

PE
11.2023

Immunotherapy with Blinatumomab in ALL

Varifarma was present at the recent course of the Peruvian Society of Hematology on Immunotherapy with Blinatumomab to explore pioneering advances in the treatment of Acute Lymphoblastic Leukemia (ALL). Dr. Laura García from Mexico gave a presentation highlighting the fundamental role of this innovative therapy and the importance of accurate patient profiling.

UY
10.2023

Present at The XVII SHA Congress

We support the Argentine Society of Hematology in the continuous medical education of professionals.

Gorax Bozatinix Binap Nibclus Nadrib Anfonax Ixafnib Lenvatib Rupovar Janvax Macyn Suprol